Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Live Attenuated Mumps Vaccine in Healthy Infants
NCT02692599Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jan 2016
- Primary completion
- Mar 2016
- Modality
- Live Attenuated Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mumps vaccine, live in mumps (2 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Seroconversion Rate at 28 days. Started Jan 2016; status: completed.
02
Drugs
mumps vaccine, live
03
Conditions
mumps
Beyond the preview
Go deeper on NCT02692599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02692599.